BRIEF published on 11/07/2024 at 07:35, 14 days 6 hours ago Semperit Reports Increased Profitability and Confirms 2024 Outlook Financial Performance 2024 Outlook Profitability Increase Semperit Group Industry Focus
PRESS RELEASE published on 11/07/2024 at 07:30, 14 days 6 hours ago Semperit increases profitability in Q1–3 and confirms outlook for 2024 Semperit Group sees increase in profitability in Q1–3 with EBITDA up 12% to EUR 63.9 million. Confirmed EBITDA guidance of around EUR 80 million for 2024 EBITDA Profitability Outlook 2024 Semperit Group
BRIEF published on 09/26/2024 at 10:10, 1 month 25 days ago Semperit: Manfred Stanek Appointed New CEO CEO Appointment Leadership Industry Semperit Manfred Stanek
BRIEF published on 09/26/2024 at 10:07, 1 month 25 days ago Manfred Stanek Appointed New CEO of Semperit AG Holding CEO Appointment Corporate Leadership Semperit Manfred Stanek Industrial Elastomers
PRESS RELEASE published on 09/26/2024 at 10:05, 1 month 25 days ago Semperit: Manfred Stanek appointed new CEO Semperit AG Holding appoints Manfred Stanek as the new CEO, bringing in a seasoned manager to lead the company towards further growth and innovation Market Position CEO Appointment Supervisory Board Semperit Manfred Stanek
PRESS RELEASE published on 09/26/2024 at 10:02, 1 month 25 days ago EQS-Adhoc: Semperit AG Holding: Manfred Stanek appointed new CEO Semperit AG Holding appoints Manfred Stanek as new CEO, succeeding Karl Haider. Stanek to join Executive Board on 1 March 2025 and assume CEO role on 1 April 2025 CEO Appointment Executive Board Semperit AG Holding Karl Haider Manfred Stanek
BRIEF published on 08/13/2024 at 07:35, 3 months 8 days ago Semperit Increases Profitability in the First Half of 2024 Profitability Free Cash Flow Cost-cutting EBITDA Growth Financial Stability
PRESS RELEASE published on 08/13/2024 at 07:30, 3 months 8 days ago Semperit increases profitability in the first half of 2024 Semperit increases profitability in the first half of 2024, with EBITDA up 8% to EUR 47.3 million, and medium-term targets set until 2026 for further growth Financial Results EBITDA Profitability Growth Targets Semperit
BRIEF published on 07/01/2024 at 08:05, 4 months 20 days ago Semperit Finalizes Sale of Remaining Medical Business Growth Strategy Semperit Medical Business Sale Harps Global Industrial Elastomer
PRESS RELEASE published on 07/01/2024 at 08:00, 4 months 20 days ago Semperit finalizes sale of the remaining medical business Semperit AG Holding successfully finalizes the sale of its remaining medical business, including surgical gloves production and packaging, to Harps Global, exiting the glove business completely Sale Semperit AG Holding Harps Global Medical Business Surgical Gloves
Published on 11/21/2024 at 13:30, 38 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 38 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 1 hour 8 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 1 hour 8 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 1 hour 8 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 33 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 53 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 10 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 48 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 23 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 23 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
